Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
Hugo Antonio Romo Rubio, Pediatric Oncologist and Faculty Member at Nuevo Hospital Civil Court of Guadalajara, Presided over by Dr. Juan I. Menchaca, shared on LinkedIn about a recent article by Maria Elisa Mancuso et al, published in NEJM:
”Hemophilia A: The FRONTIERS2 Phase 3 Study. Mim8 (Denecimig) Prophylaxis – A New Paradigm in Treatment.
The landscape of Hemophilia A management is evolving.
Results from the ‘FRONTIERS2 Phase 3 trial’ highlight the transformative potential of ‘Mim8 (denecimig)‘, a next-generation bispecific antibody, as a cornerstone for prophylactic care.
Key Highlights from the Study:
- Superior Efficacy: Mim8 prophylaxis demonstrated clear superiority in reducing bleeding episodes compared to both on-demand treatment and prior prophylaxis with coagulation factor concentrates.
- Drastic Reduction in ABR: Patients treated with Mim8 experienced up to a 98.7% reduction in the Annualized Bleeding Rate (ABR) for treated bleeds when compared to the on-demand group.
- Broad Clinical Utility: The drug proved effective across the board, including patients with and without inhibitors, as well as across varying degrees of Hemophilia A severity.
- Robust Safety Profile: Mim8 maintained a favorable safety profile throughout the study, with no reported thromboembolic events, deaths, or neutralizing antibodies.
- Superior Bleed Control: An impressive majority of participants – ranging from 64% to 95% – remained entirely free of treated bleeds during the 26-week trial period.
- Optimized Dosing Regimen: The tiered dosing model simplifies administration through low-volume subcutaneous injections. With weekly or monthly frequency options, it significantly reduces the overall treatment burden for patients.
This data reinforces Mim8’s potential to redefine the standard of care, offering patients a more flexible and highly effective path toward a zero-bleed reality.”
Title: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Authors: Maria Elisa Mancuso, Anthony K.C. Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu, Lize F.D. van Vulpen, Pratima Chowdary, Renchi Yang, Steven R. Lentz, Tadashi Matsushita, Wan Hui Ong Clausen, Ilgiz Rakhmatullin, Johannes Oldenburg for the FRONTIER2 Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event